First Time Loading...
B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 16 ILS -2.44% Market Closed
Updated: May 14, 2024

Intrinsic Value

BLRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. [ Read More ]

The intrinsic value of one BLRX stock under the Base Case scenario is 9.89 ILS. Compared to the current market price of 16 ILS, BioLine RX Ltd is Overvalued by 38%.

Key Points:
BLRX Intrinsic Value
Base Case
9.89 ILS
Overvaluation 38%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
BioLine RX Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BLRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
BioLine RX Ltd

Provide an overview of the primary business activities
of BioLine RX Ltd.

What unique competitive advantages
does BioLine RX Ltd hold over its rivals?

What risks and challenges
does BioLine RX Ltd face in the near future?

Summarize the latest earnings call
of BioLine RX Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioLine RX Ltd.

Provide P/S
for BioLine RX Ltd.

Provide P/E
for BioLine RX Ltd.

Provide P/OCF
for BioLine RX Ltd.

Provide P/FCFE
for BioLine RX Ltd.

Provide P/B
for BioLine RX Ltd.

Provide EV/S
for BioLine RX Ltd.

Provide EV/GP
for BioLine RX Ltd.

Provide EV/EBITDA
for BioLine RX Ltd.

Provide EV/EBIT
for BioLine RX Ltd.

Provide EV/OCF
for BioLine RX Ltd.

Provide EV/FCFF
for BioLine RX Ltd.

Provide EV/IC
for BioLine RX Ltd.

Show me price targets
for BioLine RX Ltd made by professional analysts.

What are the Revenue projections
for BioLine RX Ltd?

How accurate were the past Revenue estimates
for BioLine RX Ltd?

What are the Net Income projections
for BioLine RX Ltd?

How accurate were the past Net Income estimates
for BioLine RX Ltd?

What are the EPS projections
for BioLine RX Ltd?

How accurate were the past EPS estimates
for BioLine RX Ltd?

What are the EBIT projections
for BioLine RX Ltd?

How accurate were the past EBIT estimates
for BioLine RX Ltd?

Compare the revenue forecasts
for BioLine RX Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioLine RX Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioLine RX Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioLine RX Ltd compared to its peers.

Compare the P/E ratios
of BioLine RX Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing BioLine RX Ltd with its peers.

Analyze the financial leverage
of BioLine RX Ltd compared to its main competitors.

Show all profitability ratios
for BioLine RX Ltd.

Provide ROE
for BioLine RX Ltd.

Provide ROA
for BioLine RX Ltd.

Provide ROIC
for BioLine RX Ltd.

Provide ROCE
for BioLine RX Ltd.

Provide Gross Margin
for BioLine RX Ltd.

Provide Operating Margin
for BioLine RX Ltd.

Provide Net Margin
for BioLine RX Ltd.

Provide FCF Margin
for BioLine RX Ltd.

Show all solvency ratios
for BioLine RX Ltd.

Provide D/E Ratio
for BioLine RX Ltd.

Provide D/A Ratio
for BioLine RX Ltd.

Provide Interest Coverage Ratio
for BioLine RX Ltd.

Provide Altman Z-Score Ratio
for BioLine RX Ltd.

Provide Quick Ratio
for BioLine RX Ltd.

Provide Current Ratio
for BioLine RX Ltd.

Provide Cash Ratio
for BioLine RX Ltd.

What is the historical Revenue growth
over the last 5 years for BioLine RX Ltd?

What is the historical Net Income growth
over the last 5 years for BioLine RX Ltd?

What is the current Free Cash Flow
of BioLine RX Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioLine RX Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioLine RX Ltd

Current Assets 47.2m
Cash & Short-Term Investments 43m
Receivables 1.2m
Other Current Assets 3m
Non-Current Assets 16.7m
PP&E 1.9m
Intangibles 14.9m
Current Liabilities 30.9m
Accounts Payable 14.2m
Other Current Liabilities 16.6m
Non-Current Liabilities 19.9m
Long-Term Debt 7.9m
Other Non-Current Liabilities 11.9m
Efficiency

Earnings Waterfall
BioLine RX Ltd

Revenue
4.8m USD
Cost of Revenue
-3.7m USD
Gross Profit
1.1m USD
Operating Expenses
-44.1m USD
Operating Income
-43m USD
Other Expenses
-17.6m USD
Net Income
-60.6m USD

Free Cash Flow Analysis
BioLine RX Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BLRX Profitability Score
Profitability Due Diligence

BioLine RX Ltd's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

14/100
Profitability
Score

BioLine RX Ltd's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

BLRX Solvency Score
Solvency Due Diligence

BioLine RX Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
40/100
Solvency
Score

BioLine RX Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BLRX Price Targets Summary
BioLine RX Ltd

Wall Street analysts forecast BLRX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BLRX is 3 ILS .

Lowest
Price Target
Not Available
Average
Price Target
3 ILS
81% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BLRX Price
BioLine RX Ltd

1M 1M
-12%
6M 6M
-56%
1Y 1Y
-55%
3Y 3Y
-76%
5Y 5Y
-88%
10Y 10Y
-100%
Annual Price Range
16
52w Low
15.1
52w High
62.3
Price Metrics
Average Annual Return -35.58%
Standard Deviation of Annual Returns 34.41%
Max Drawdown -91%
Shares Statistics
Market Capitalization 162.5m ILS
Shares Outstanding 10 158 352
Percentage of Shares Shorted
N/A

BLRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

BioLine RX Ltd

Country

Israel

Industry

Biotechnology

Market Cap

162.5m ILS

Dividend Yield

0%

Description

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact

Modiin
Modi'in Technology Park, 2 HaMa'ayan Street
+97286429100.0
http://www.biolinerx.com/

IPO

2007-01-30

Employees

38

Officers

Chief Executive Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Financial Officer
Ms. Mali Zeevi CPA, CPA
Chief Development Officer
Dr. Ella Sorani Ph.D.
President of BioLineRx USA
Ms. Holly W. May M.B.A.
Head of Corporate Communications & Investor Relations
Mr. John Lacey
Head of BD & Strategic Advisor
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Show More
Treasurer & Budgetary Control Director
Mr. Raziel Fried
Show Less

See Also

Discover More
What is the Intrinsic Value of one BLRX stock?

The intrinsic value of one BLRX stock under the Base Case scenario is 9.89 ILS.

Is BLRX stock undervalued or overvalued?

Compared to the current market price of 16 ILS, BioLine RX Ltd is Overvalued by 38%.